Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OmegaBrite
- Development stage
- Unknown
- Lead developer
- OmegaBrite
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
OmegaBrite is a high-potency omega-3 fatty acid supplement featuring a concentrated 7:1 ratio of eicosapentaenoic acid (EPA) to docosahexaenoic acid (DHA). It has been extensively studied in clinical trials sponsored by the National Institute of Mental Health (NIMH) as an adjunctive treatment for bipolar disorder, including bipolar depression and rapid-cycling subtypes. The supplement is thought to exert its therapeutic effects by modulating neuronal signal transduction pathways and reducing neuroinflammation, mechanisms that may complement traditional mood stabilizers. As a small molecule nutraceutical, it is administered orally in capsule form.
- Brand names
- OmegaBrite
- Other names
- omega-3 fatty acidsomega3 fatty acidsomega 3 fatty acidsEthyl Eicosapentaenoic AcidEPADHAeicosapentaenoic aciddocosahexaenoic acid
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)FFAR4 (Free fatty acid receptor 4)
Beyond the preview
Go deeper on OmegaBrite.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OmegaBrite.